Navigation Links
Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
Date:1/19/2011

rm technology to develop products in other key therapeutic areas including inflammatory disease and orthopedic injury.

Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, Highland Capital Partners and the Richter Family Fund. For more information, please visit www.pervasistx.com.  

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.

(1) J. W. Franses, A. B. Baker, V. C. Chitalia, E. R. Edelman, Stromal Endothelial Cells Directly Influence Cancer Progression. Sci. Transl. Med. 3, 66ra5 (2011).Company Contact: Margaret O'Toole Pervasis Therapeutics, Inc. 617-871-1201 motoole@pervasistx.comMedia Contact: Liz Falcone Feinstein Kean Healthcare 617-256-6622liz.falcone@fkhealth.com
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
2. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
3. PTC Therapeutics President and CEO Elected AAAS Fellow
4. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
5. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
6. Echo Therapeutics to Present at the OneMedForum 2011 Conference
7. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
8. Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
9. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
10. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Revenue and earnings above the previous year - ... In the past 2013/14 fiscal year (ended 30 September ... 4.287 billion (last year: EUR 4.190 billion) despite unfavorable currency ... million. "Overall, 2013/14 was a successful fiscal year for the ... CEO of Carl Zeiss AG. "Thanks to our broad portfolio ...
(Date:12/17/2014)... 17, 2014 , ... a hub of information concerning the biopharmaceutical Group,s national and ... further addition to the recently launched institutional website that is ... been enriched by a new chapter in the fascinating story ... richly detailed and panoramic hub on the world of clinical ...
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... Medical Simulation Corporation (MSC) is proud to offer ... seeking funding through the Health Care Innovation Challenge, announced ... and Human Services. Simulation provides a unique, ... their skills in managing patients with diagnoses associated with ...
... YORK, Nov. 15, 2011 Reportlinker.com announces ... available in its catalogue: ... Asia http://www.reportlinker.com/p0203106/The-Outlook-for-Pharmaceuticals-in-South-East-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... South East Asia are developing at markedly ...
Cached Medicine Technology:Medical Simulation Corporation Offers Innovative Training Solutions for Healthcare Organizations Applying to the Department of Health and Human Services' Health Care Innovation Challenge 2The Outlook for Pharmaceuticals in South East Asia 2The Outlook for Pharmaceuticals in South East Asia 3The Outlook for Pharmaceuticals in South East Asia 4The Outlook for Pharmaceuticals in South East Asia 5
(Date:12/17/2014)... News) -- Expectant parents should leave prenatal picture-taking to ... Use of ultrasound imaging and heartbeat monitors to ... the agency warns. "Although there is a ... imaging and heartbeat monitors, prudent use of these devices ... an FDA biomedical engineer, said in an agency news ...
(Date:12/17/2014)... Amy Norton HealthDay ... Yoga has long been believed to improve overall health, but ... also help the heart, a new review finds. In ... such as brisk walking, said lead researcher Paula Chu, a ... The review, of 37 clinical trials, found that people ...
(Date:12/15/2014)... December 15, 2014 Veretekk.com, Inc. announced ... Ocean Avenue. JM Ocean Avenue has secured exclusive ... online automated marketing system. JM Ocean Avenue is ... merger of Ocean Avenue and JM International, with partial ... Billion per year company. , “After nearly 2 decades ...
(Date:12/15/2014)... OutMarket , a provider of marketing automation ... Sheets ,” a guide that exposes the insider secrets ... top ten social media networks. , Social media ... and customer service. It can also increase new leads ... new networks and weather constantly changing algorithms, they need ...
(Date:12/15/2014)... Dallas,TX (PRWEB) December 15, 2014 The increase ... is one of the main factors which is contributing to ... used for the diagnosis and treatment of hearing loss and ... comprises of three parts - microphone, speaker and amplifier. The ... growth rate of 6.01% during the period from 2014 to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... , , DETROIT, Aug. 6 ... Blue Shield of Michigan to help a movement that has made ... , One of those doctors is Michael Schaub ... of doctors, scrawl on prescriptions they write in their family practice. ...
... , , , SPARKS, ... BD (Becton, Dickinson and Company) (NYSE: BDX ), announced today ... diseases by adding software systems for the surveillance of infections and associated ... , , Through the acquisition of ICPA, Inc., ...
... , , , ... biopharmaceutical company focused on changing the paradigm of drug discovery and ... of Dr. Chad Cowan and Dr. Konrad Hochedlinger to the company,s ... and Hochedlinger are leading scientists in stem cell research and their ...
... , , BOSTON, Aug. 6 ... is pleased to announce their full agenda which includes Dr. Paul ... Foundation, as the keynote speaker for the inaugural Access ... forum will take place at the Hilton in Alexandria, VA, on ...
... no cure, survey finds , THURSDAY, Aug. 6 (HealthDay News) ... daily medicine can be taken to prevent a food allergy ... of knowledge and awareness about food allergy among the general ... that nearly half of respondents incorrectly believed that there is ...
... , , , ... Wyse Technology , the global leader in thin computing and client ... . Kool Smiles is a rapidly-growing company whose mission is to ... Since opening its first office in 2002 in Atlanta, GA, the network ...
Cached Medicine News:Health News:Efforts by Blue Cross Blue Shield of Michigan, Physician Practices Help Michigan Become a Leading Adopter of E-prescribing 2Health News:Efforts by Blue Cross Blue Shield of Michigan, Physician Practices Help Michigan Become a Leading Adopter of E-prescribing 3Health News:BD Adds Surveillance Capability to Infectious Disease Portfolio 2Health News:BD Adds Surveillance Capability to Infectious Disease Portfolio 3Health News:iPierian Appoints Dr. Chad Cowan and Dr. Konrad Hochedlinger to Scientific Advisory Board 2Health News:CBI Announces the Agenda for Their Upcoming Access Federal Stimulus Incentives for Electronic Health Records Conference 2Health News:Food Allergy Facts Need More Focus 2Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 2Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 3Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 4Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 5
Cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Cross action, round handle, maximum opening 2.8 mm....
Medicine Products: